31 results on '"Dumont, Anael"'
Search Results
2. Drugs associated with systemic sclerosis: An updated list of suspected drugs using the WHO pharmacovigilance database
- Author
-
Dumont, Anaël, Dolladille, Charles, de Boysson, Hubert, Alexandre, Joachim, Nguyen, Alexandre, Deshayes, Samuel, and Aouba, Achille
- Published
- 2022
- Full Text
- View/download PDF
3. Assessment of social deprivation and socioeconomic factors in patients with giant cell arteritis
- Author
-
Delort, Diane, Philip, Rémi, Gallou, Sophie, Dumont, Anael, Deshayes, Samuel, Boutemy, Jonathan, Maigné, Gwénola, Martin Silva, Nicolas, Nguyen, Alexandre, Launoy, Guy, Launay, Ludivine, Aouba, Achille, and de Boysson, Hubert
- Published
- 2024
- Full Text
- View/download PDF
4. VEXAS syndrome: A new mimicker of idiopathic multicentric Castleman disease
- Author
-
Philip, Rémi, Cadro, Vincent, Aouba, Achille, Chantepie, Sylvain, Bracquemart, Claire, and Dumont, Anaël
- Published
- 2024
- Full Text
- View/download PDF
5. Thyroid disorders in familial Mediterranean fever: think about AA amyloidosis!
- Author
-
Vergneault, Hélène, Bourguiba, Rim, Ardois, Samuel, Dumont, Anael, Savey, Léa, Grateau, Gilles, and Georgin-Lavialle, Sophie
- Published
- 2021
- Full Text
- View/download PDF
6. Giant cell arteritis presenting as isolated inflammatory response and/or fever of unknown origin: a case-control study
- Author
-
de Boysson, Hubert, Liozon, Eric, Ly, Kim Heang, Dumont, Anael, Delmas, Claire, Sultan, Audrey, and Aouba, Achille
- Published
- 2018
- Full Text
- View/download PDF
7. Evolution of the Therapeutic Management of Giant Cell Arteritis: Analysis of Real-Life Practices over Two Timeframes (2014–2017 and 2018–2020).
- Author
-
de Boysson, Hubert, Dumont, Anael, Castan, Paul, Gallou, Sophie, Boutemy, Jonathan, Maigné, Gwénola, Martin Silva, Nicolas, Nguyen, Alexandre, Deshayes, Samuel, and Aouba, Achille
- Subjects
- *
GIANT cell arteritis , *CELL analysis , *TIME measurements - Abstract
Objectives: To determine how therapeutic strategies for giant cell arteritis (GCA), especially glucocorticoid (GC) management, evolved between 2014 and 2020. Patients and Methods: Consecutive GCA patients followed for at least 24 months in a single tertiary center were enrolled and separated into two groups: those diagnosed from 2014 to 2017 and those diagnosed from 2018 to 2020. GC doses (mg/kg/day) were analyzed at onset, at Month 3 (M3) and, if continued, at M6, M12, M18 and M24. Physicians' practices were also individually analyzed. Results: Among the 180 patients included, 96 (53%) were diagnosed in 2014–2017 and 84 (47%) in 2018–2020. All patients received GC at diagnosis without a difference in the initial dose between the two groups (p = 0.07). At M3, the daily dose was lower in patients treated after 2017 (p = 0.002). In patients who still received GC at M6 (p = 0.0008), M12 (p = 0.01) and M24 (p = 0.02), the daily GC dose was still lower in patients treated after 2017. The proportion of patients who definitively discontinued GC use before M18 (42% versus 21%, p = 0.003) was higher in those treated after 2017. The rates of immunosuppressant use were not different between the two time periods (31% versus 38%, p = 0.34), but tocilizumab replaced methotrexate. Significant differences were observed among practitioners regarding the GC doses at M6 (p = 0.04) and M12 (p = 0.04), the total GC duration (p = 0.02) and the ability to stop GC before M18 (p = 0.007). Conclusions: This real-life study showed a global change in GC management over time for GCA patients, with important variability among physicians' practices. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Vascular Presentation and Outcomes of Patients With Giant Cell Arteritis and Isolated Symptomatic Limb Involvement
- Author
-
de Boysson, Hubert, Espitia, Olivier, Liozon, Eric, Daumas, Aurélie, Vautier, Mathieu, Dumont, Anael, Granel, Brigitte, Saadoun, David, Planchard, Gaétane, Ly, Kim Heang, and Aouba, Achille
- Published
- 2020
- Full Text
- View/download PDF
9. Giant-cell arteritis: concordance study between aortic CT angiography and FDG-PET/CT in detection of large-vessel involvement
- Author
-
de Boysson, Hubert, Dumont, Anael, Liozon, Eric, Lambert, Marc, Boutemy, Jonathan, Maigné, Gwénola, Martin Silva, Nicolas, Sultan, Audrey, Ly, Kim Heang, Aide, Nicolas, Manrique, Alain, Bienvenu, Boris, and Aouba, Achille
- Published
- 2017
- Full Text
- View/download PDF
10. An updated list of drugs suspected to be associated with immune thrombocytopenia based on the WHO pharmacovigilance database
- Author
-
Fuentes, Ségolène, Chrétien, Basile, Dolladille, Charles, Alexandre, Joachim, Dumont, Anaël, Nguyen, Alexandre, de Boysson, Hubert, Chèze, Stéphane, Maigné, Gwénola, Aouba, Achille, and Deshayes, Samuel
- Published
- 2022
- Full Text
- View/download PDF
11. Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients.
- Author
-
Khitri, Mohamed-Yacine, Guedon, Alexis F., Georgin-Lavialle, Sophie, Terrier, Benjamin, Saadoun, David, Seguier, Julie, le Besnerais, Maelle, De Moreuil, Claire, Denis, Guillaume, Gerfaud-Valentin, Mathieu, Allain, Jean Sebastien, Maria, Alexandre, Bouillet, Laurence, Grobost, Vincent, Galland, Joris, Kosmider, Olivier, Dumont, Anael, Devaux, Mathilde, Subran, Benjamin, and Schmidt, Jean
- Published
- 2022
- Full Text
- View/download PDF
12. Tolerance of glucocorticoids in giant cell arteritis: a study of patient-reported adverse events.
- Author
-
Boysson, Hubert de, Barakat, Clivia, Dumont, Anael, Boutemy, Jonathan, Silva, Nicolas Martin, Maigné, Gwénola, Nguyen, Alexandre, Lavergne, Amandine, Castan, Paul, Gallou, Sophie, Sultan, Audrey, Deshayes, Samuel, and Aouba, Achille
- Subjects
GLUCOCORTICOIDS ,CATARACT ,CARDIOVASCULAR diseases risk factors ,SKIN ,GIANT cell arteritis ,HEALTH outcome assessment ,COGNITION ,OSTEOPOROSIS ,DESCRIPTIVE statistics ,BONE fractures ,EVALUATION - Abstract
Objective To assess patients' self-reported glucocorticoid (GC)-related adverse events (AEs) in a GCA population. Methods A questionnaire was sent to the 100 patients most recently diagnosed with GCA in a tertiary centre. This questionnaire included open- and close-ended questions on the disease and GC effects. Eight primary AE areas were analysed: cardiovascular, metabolic, muscle, cognitive and psychologic, bone, cutaneous and hairiness, infective and visual complications. Including derivative subitems from preceding areas, a total of 18 GC-related AEs were analysed separately and according to GC duration. Results Ninety patients were analysed and 89 (99%) reported at least one GC-related AE [median 6 (range 1–11)]. Cognitive and psychological changes, primarily insomnia (72%), affected 90% of patients. Cutaneous changes and muscle loss affected 70% of patients, with frequent impairment of physical autonomy (P = 0.007) associated with this event. Metabolic issues, especially weight gain (40%) and diabetes mellitus (20%), affected 49% of patients. Conversely, vision troubles and bone fractures were mentioned by 42% and 9% of patients, respectively, and more frequently in patients who received GCs for >18 months (P = 0.01 and P = 0.007, respectively). Cardiovascular changes and infections affected 30% and 26% of patients, respectively. Conclusion This real-life study of GC tolerance assessed using a self-evaluation provides pragmatic and updated data reminding us that GC tolerance remains more noteworthy than ever. This study suggests carefully monitoring GC-related AEs during follow-up and encourages GC-sparing strategies in some patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Real-life analysis of the causes of death in patients consecutively followed for giant cell arteritis in a French centre of expertise.
- Author
-
Antonini, Luca, Dumont, Anael, Lavergne, Amandine, Castan, Paul, Barakat, Clivia, Gallou, Sophie, Sultan, Audrey, Deshayes, Samuel, Aouba, Achille, and Boysson, Hubert de
- Subjects
- *
GIANT cell arteritis diagnosis , *CAUSES of death , *GLUCOCORTICOIDS , *CONFIDENCE intervals , *STROKE , *FEVER , *GERIATRICS , *MULTIVARIATE analysis , *GIANT cell arteritis , *CARDIOVASCULAR diseases , *RISK assessment , *INFECTION , *COMPARATIVE studies , *OSTEOPOROSIS , *TUMORS ,MORTALITY risk factors - Abstract
Objectives To describe, in a real-life setting, the direct causes of death in a cohort of consecutive patients with GCA. Methods We retrospectively analysed the deaths that occurred in a cohort of 470 consecutive GCA patients from a centre of expertise between January 2000 and December 2019. Among the 120 patients who died, we retrieved data from the medical files of 101 patients. Results Cardiovascular events were the dominant cause of death (n = 41, 41%) followed by infections (n = 22, 22%), geriatric situations (i.e. falls or senile deterioration; n = 17, 17%) and cancers (n = 15, 15%). Patients in each of these four groups were compared with the other deceased patients pooled together. Patients who died from cardiovascular events were more frequently male (46 vs 27%; P = 0.04) with a past history of coronary artery disease (29 vs 8%; P = 0.006). Patients who died from infections mostly had ongoing glucocorticoid treatment (82 vs 53%; P = 0.02) with higher cumulative doses (13 994 vs 9150 mg; P = 0.03). Patients who died from geriatric causes more frequently had osteoporosis (56 vs 17%; P = 0.0009) and had mostly discontinued glucocorticoid treatment (76 vs 33%; P = 0.001). The predictive factors of death in multivariate analysis were a history of coronary disease [hazard ratio (HR) 2.39; 95% CI 1.27, 4.21; P = 0.008], strokes at GCA diagnosis (HR 2.54; 95% CI 1.05, 5.24; P = 0.04), any infection during follow-up (HR 1.93; 95% CI 1.24, 2.98; P = 0.004) and fever at GCA diagnosis (HR 1.99; 95% CI 1.16, 3.28; P = 0.01). Conclusion Our study provides real-life insight on the cause-specific mortality in GCA patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Giant-Cell Arteritis: Do We Treat Patients with Large-Vessel Involvement Differently?
- Author
-
de Boysson, Hubert, Liozon, Eric, Lambert, Marc, Dumont, Anael, Boutemy, Jonathan, Maigné, Gwénola, Martin Silva, Nicolas, Ly, Kim Heang, Manrique, Alain, Bienvenu, Boris, and Aouba, Achille
- Published
- 2017
- Full Text
- View/download PDF
15. Giant cell arteritis-related aortic dissection: A multicenter retrospective study.
- Author
-
de Boysson, Hubert, Espitia, Olivier, Samson, Maxime, Tieulié, Nathalie, Bachmeyer, Claude, Moulinet, Thomas, Dumont, Anael, Deshayes, Samuel, Bonnotte, Bernard, Agard, Christian, and Aouba, Achille
- Abstract
• Giant-cell arteritis-related aortic dissection occurs earlier in patients with aortitis than in those without. • 70% of patients presented Stanford type A aortic dissection. • Half of patients with type a dissection had a previous thoracic aorta dilation. • Aortic surgery is the single predictive factor for survival in patients with GCA-related aortic dissection. To describe characteristics and outcomes of patients with giant cell arteritis (GCA)-related aortic dissection. We retrospectively included, through a nationwide GCA network, all patients who had an aortic dissection either revealing GCA or occurring during follow-up. A total of 46 patients were included in this study. Aortic dissection was inaugural and led to GCA diagnosis in 21 patients, whereas it occurred during follow-up in the 25 others, at a median of 53 [1–265] months after GCA diagnosis. Large-vessel vasculitis (LVV) was diagnosed through imaging before or at the time of aortic dissection in 31 (67%) patients. In patients who developed an aortic dissection during follow-up, the aortic event occurred 22 [1–143] months post GCA diagnosis in the patients with previous aortitis, whereas it occurred after 72 [19–265] months in patients without previously diagnosed aortitis (p = 0.005). Aortic surgery was performed in 27 (59%) patients and 23 of them survived. A total of 15 (32%) patients died following the aortic dissection, including 11 who were not operated on. In a multivariate analysis, aortic surgery was the single predictor of survival (HR: 4.3; 95% CI: 1.47— 15.7; p = 0.007). Patients with prior LVV are more prone to develop early aortic dissection and require close monitoring of aortic morphology. One third of patients died from the aortic dissection. Surgery remains the best predictive factor for survival. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
16. Typical Familial Mediterranean Fever associated with the heterozygous missense sequence p.T577N variant of the MEFV gene: Report on two Northern European Caucasians relatives in France.
- Author
-
Elhani, Ines, Dumont, Anael, Deshayes, Samuel, Georgin-Lavialle, Sophie, Giurgea, Irina, and Aouba, Achille
- Subjects
- *
FAMILIAL Mediterranean fever , *GENETIC mutation , *CAUCASIAN race , *GAIN-of-function mutations , *FATHER-daughter relationship , *RECESSIVE genes - Abstract
Introduction: Familial Mediterranean fever is the most frequent monogenic auto-inflammatory disorder that mostly affects Mediterranean population. Although this auto-inflammatory disease has historically been described as a recessive genetic disorder with homozygous or compound heterozygous mutations in the MEFV gene, an increasing number of cases are described with the detection of new single MEFV gene heterozygous mutations with modern molecular techniques.Case Description: We report the cases of Caucasian French descent father and daughter who exhibited joint and abdominal inflammatory attacks resembling Familial Mediterranean Fever. Genetic studies revealed in both a heterozygous mutation p.T577N in exon 8 of MEFV gene, and in which colchicine was effective for preventing the attacks.Conclusion: Single heterozygous mutation of MEFV can be responsible for typical Familial Mediterranean Fever clinical pattern and, what is more, in non-Mediterranean ethnic background patients. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
17. Factors Associated with Relapse and Dependence on Glucocorticoids in Giant Cell Arteritis.
- Author
-
Dumont, Anael, Parienti, Jean-Jacques, Delmas, Claire, Boutemy, Jonathan, Maigné, Gwénola, Silva, Nicolas Martin, Sultan, Audrey, Planchard, Gaétane, Aouba, Achille, de Boysson, Hubert, and Martin Silva, Nicolas
- Published
- 2020
- Full Text
- View/download PDF
18. Features and prognosis of giant cell arteritis in patients over 85 years of age: A case-control study.
- Author
-
Liozon, Eric, Delmas, Claire, Dumonteil, Stéphanie, Dumont, Anael, Gondran, Guillaume, Bezanahary, Holy, Aouba, Achille, Fauchais, Anne-Laure, Ly, Kim-Heang, and de Boysson, Hubert
- Abstract
We examined the initial features, course, and prognosis of giant cell arteritis (GCA) in patients ≥ 85 years of age (≥85 year) and compared them to those of younger patients. The present retrospective study included all patients who were newly diagnosed with GCA in the Internal Departments of two French University Hospitals from 1976 or 1998 to 2017 and who were followed up for at least 6 months. Logistic regression analyses were conducted to identify baseline and prognostic characteristics associated with being ≥85 year. Of the 865 patients assessed in this study, 87 were ≥85 year. Compared to younger patients, patients ≥ 85 year had more comorbid conditions (odds ratio [OR] = 1.11–1.74, p < 0.01), less often exhibited polymyalgia rheumatica (PMR; OR = 0.33–0.96, p = 0.04), and more often developed permanent visual loss (OR = 1.29–3.81, p < 0.01). The older patients also showed less dependence on glucocorticoid (GC) medications (OR = 0.23–0.94, p = 0.04), had fewer relapses (OR = 0.31–0.87, p = 0.015), less often recovered from GCA (OR = 0.22–0.69, p < 0.01), and more often died during treatment (OR = 1.45–4.65, p = 0.001) compared to younger patients. Being ≥85 year was the only factor associated with an increased 1-year mortality (hazard ratio = 1.77–5.81, p = 0.0001) for the whole cohort. GCA in very elderly patients was characterized by a higher rate of severe ischemic complications and an increased risk for early death compared to younger patients. Thus, there is a need for the early diagnosis of GCA and close clinical monitoring in this unique population. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
19. Impact of Glucocorticoid Cumulative Doses in a Real-Life Cohort of Patients Affected by Giant Cell Arteritis.
- Author
-
Castan, Paul, Dumont, Anael, Deshayes, Samuel, Boutemy, Jonathan, Martin Silva, Nicolas, Maigné, Gwénola, Nguyen, Alexandre, Gallou, Sophie, Sultan, Audrey, Aouba, Achille, and de Boysson, Hubert
- Subjects
- *
GIANT cell arteritis , *HERPES zoster , *GLUCOCORTICOIDS , *BONE fractures , *WEIGHT gain - Abstract
Objectives: To describe the impact of cumulative glucocorticoid (GC) doses on related adverse events (AEs) in giant cell arteritis (GCA) in a real-life setting. Methods: The medical charts of the last 139 consecutive GCA patients followed in a tertiary centre were retrospectively analysed. The cumulative GC doses were calculated, and the main GC-related AEs were collected during the follow-up. Results: After a median follow-up duration of 35.6 (2–111) months, the median cumulative GC dose in the 139 patients was 9184 (1770–24,640) mg, and 131 patients (94%) presented at least one GC-related AE. Infections (63%) were the most frequently reported GC-related AE, followed by metabolic events (63%), including weight gain in 51% of them. Cardiovascular and neuropsychiatric events occurred in 51% and 47% of patients, respectively. Osteoporotic fractures, muscular involvement, digestive events, geriatric deterioration, skin fragility, ophthalmologic complications and hypokalaemia were reported in <35% of patients. Cardiovascular events (p = 0.01), osteoporotic fractures (p = 0.004), cataract occurrence (p = 0.03), weight gain (p = 0.04) and infections (p = 0.01) were significantly associated with GC cumulative doses > 9 g. Longer GC durations were associated with cataract occurrence (p = 0.01), weight gain (p = 0.03) and all-grade infections (p = 0.048), especially herpes zoster occurrence (p = 0.003). Neuropsychiatric and metabolic events appeared within the first months after GC introduction, whereas herpes zoster recurred, and most cardiovascular AEs emerged after 1 year. Geriatric events, especially osteoporotic fractures, occurred 2 years after GC introduction. Conclusion: This study highlights how frequent GC-related AEs are and the impact of prolonged GC and cumulative doses. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
20. ANCA and anti-glomerular basement membrane double-positive patients: A systematic review of the literature.
- Author
-
Philip, Rémi, Dumont, Anael, Martin Silva, Nicolas, de Boysson, Hubert, Aouba, Achille, and Deshayes, Samuel
- Subjects
- *
BASAL lamina , *ACUTE kidney failure , *ANTINEUTROPHIL cytoplasmic antibodies , *SURVIVAL rate , *NEPHRITIS - Abstract
Double-positive patients (DPP) exhibiting anti-glomerular basement membrane (GBM) and anti-neutrophil cytoplasmic antibodies (ANCAs) belong to an entity that is newly and poorly described, mainly in short series. We aimed to better characterize the epidemiological features, clinical presentation and therapeutic outcomes of these patients through a systematic review. We performed a systematic review of English-, German-, Spanish- and French-written publications from February 1987 to March 2020 reporting cases of DPP using the following databases: PubMed, Scielo, ScienceDirect, Google Scholar, The Cochrane Library, Open Grey, The Grey Literature Report, Clinicaltrials.gov and International Clinical Trial Registry Platform of the World Health Organization. In total, 538 DPP were identified from 90 articles. Their clinical presentations were often severe, and the majority exhibited acute kidney failure (91.8%) with a median initial serum creatinine level of 873 μmol/L; 50.7% had alveolar haemorrhage. Other manifestations were present in 30.3% of DPP, mainly ear, nose, throat and articular manifestations. ANCAs were predominantly directed against MPO (n = 377/523; 72.1%) compared to PR3 (n = 107/523; 20.5%), with rare cases of triple positivity (n = 15/538; 2.9%). Although most patients received initial immunosuppressive therapy (n = 285/317; 89.9%), the one-year overall, renal and relapse-free survival rates were 64.8%, 38.7% and 71.1%, respectively. DPP are associated with the characteristics of two eponymous vasculitis types, responsible for a poor overall and renal prognosis. Thus, simultaneous testing of both antibodies and systematic renal biopsy should be recommended in every patient with rapidly progressive glomerulonephritis to recognize this difficult-to-treat and rare disease. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
21. Association between familial Mediterranean fever and multiple sclerosis: A case series from the JIR cohort and systematic literature review.
- Author
-
Elhani, Inès, Dumont, Anael, Vergneault, Hélène, Ardois, Samuel, Le Besnerais, Maëlle, Levesque, Hervé, Ouallet, Jean-Christophe, Savey, Léa, Aouba, Achille, Amselem, Serge, Giurgea, Irina, Capron, Jean, Grateau, Gilles, and Georgin-Lavialle, Sophie
- Abstract
• MEFV heterozygosity is not associated with multiple sclerosis (MS). • MS is more frequent in familial Mediterranean fever (FMF) patients. • MS is more likely to lack oligoclonal bands when associated with FMF. • MS should be suspected upon neurological manifestations in FMF. • The association between FMF and MS is plausible but remains to be confirmed. Familial Mediterranean fever (FMF) is the most frequent monogenic autoinflammatory disorder; and leads to the uncontrolled production of interleukin (IL)-1β. Multiple sclerosis (MS) is an inflammatory disease of the central nervous system; and its development seems to be partly correlated with IL-1β levels. It is hypothesized that FMF could be associated with MS. We aim to describe the features of patients displaying both diseases and to investigate the MEFV mutation rate in MS patients. Patients with definite MS were retrieved from the cohort of FMF patients in the Reference Center for Rare Auto-inflammatory Diseases and Amyloidosis (CEREMAIA). We also performed a systematic literature review of articles from PubMed that were published from 1990 to 2020. Twenty-four patients were included in the case series: five patients (1.3%) from our cohort of 364 and 19 patients from the literature. The sex ratio was 2:1. The mean age at diagnosis of FMF was 19 years old; and that for MS was 29 years old. Seven studies investigating the MEFV mutation rate in MS patients were included. Three studies found a higher mutation rate in MS patients than in the control group. FMF and MS features were comparable to those of patients with unrelated diseases; and MEFV mutation carriage was not positively correlated with MS. However; MS prevalence in FMF patients was higher than was expected in a healthy population. To a lesser extent; FMF prevalence in MS patients was higher than expected in a healthy population and the difference might not be significant. These data suggest that FMF could be associated with MS; and further studies are needed to investigate a potential causal association. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
22. Amyloid Goiter in Familial Mediterranean Fever: Description of 42 Cases from a French Cohort and from Literature Review.
- Author
-
Vergneault, Hélène, Terré, Alexandre, Buob, David, Buffet, Camille, Dumont, Anael, Ardois, Samuel, Savey, Léa, Pardon, Agathe, Michel, Pierre-Antoine, Boffa, Jean-Jacques, Grateau, Gilles, Georgin-Lavialle, Sophie, Touïtou, Isabelle, and van der Hilst, Jeroen
- Subjects
FAMILIAL Mediterranean fever ,CARDIAC amyloidosis ,GOITER ,NEEDLE biopsy ,LITERATURE reviews ,AMYLOIDOSIS ,THYROID diseases - Abstract
Our aim was to describe the main features of amyloid goiter in adults with amyloidosis secondary to familial Mediterranean fever. Therefore, we analyzed cases from a French cohort of familial Mediterranean fever patients with amyloidosis and from literature review. Forty-two cases were identified: 9 from the French cohort and 33 from literature review. Ninety percent of patients were on hemodialysis for renal amyloidosis before the development of goiter. The goiter grew up rapidly in 88% of cases; 75.6% of patients were euthyroid, 58% displayed dyspnea, and 44.8% dysphagia. Various features were seen on ultrasound, from diffuse to multinodular goiter. When it was performed, fine-needle aspiration biopsy almost always revealed amyloidosis. Thirty-one patients underwent thyroidectomy: to manage compressive symptoms (72%) or rule out malignancy (27%). Histology showed mature adipose tissue in 64% of cases and lymphocytic infiltration in 21.4%. In conclusion, amyloid goiter in familial Mediterranean fever preferentially occurs in patients with end stage renal failure. Fine-needle aspiration biopsy seems to be a sensitive exam for diagnosis, but thyroidectomy remains sometimes necessary to rule out malignancy or release compressive symptoms. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
23. Large-vessel involvement and aortic dilation in giant-cell arteritis. A multicenter study of 549 patients.
- Author
-
de Boysson, Hubert, Daumas, Aurélie, Vautier, Mathieu, Parienti, Jean-Jacques, Liozon, Eric, Lambert, Marc, Samson, Maxime, Ebbo, Mikael, Dumont, Anael, Sultan, Audrey, Bonnotte, Bernard, Manrique, Alain, Bienvenu, Boris, Saadoun, David, and Aouba, Achille
- Subjects
- *
GIANT cell arteritis , *AORTIC diseases , *MEDICAL centers , *POLYMYALGIA rheumatica , *FOLLOW-up studies (Medicine) - Abstract
Objectives Large-vessel involvement (LVI) can occur in giant-cell arteritis (GCA) and may represent a distinct disease subgroup with a higher risk for aortic dilation. This study aimed to better characterize the presentation and evolution of LVI in patients with GCA. Patients and methods A retrospective multicenter study enrolled 248 GCA patients with LVI and 301 GCA patients without LVI on imaging. Factors associated with aortic dilation were identified in a multivariable model. Results The patients with LVI were younger (p < 0.0001), more likely to be women (p = 0.01), and showed fewer cephalic symptoms (p < 0.0001) and polymyalgia rheumatica (p = 0.001) but more extracranial vascular symptoms (p = 0.05) than the patients without LVI. Glucocorticoids (GC) management did not differ between the two groups, but the GC discontinuation rate was lower in the patients with LVI (p = 0.0003). Repeated aortic imaging procedures were performed at 19 months [range: 5–162 months] and 17 months [range: 6–168 months] after diagnosis in 154 patients with LVI and 123 patients without LVI, respectively, of whom 21% and 7%, respectively, presented new aortic dilations (p = 0.0008). In the patients with LVI, aortic dilation occurred on an aorta segment shown to be inflammatory on previous imaging in 94% of patients. In the multivariate analysis, LVI was the strongest predictor of aortic dilation (hazard ratio: 3.16 [range: 1.34–7.48], p = 0.009). Conclusions LVI represents a distinct disease pattern of GCA with an increased risk of aortic dilation. Control of the aortic morphology during follow-up is required. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
24. Different patterns and specific outcomes of large-vessel involvements in giant cell arteritis.
- Author
-
de Boysson, Hubert, Liozon, Eric, Espitia, Olivier, Daumas, Aurélie, Vautier, Mathieu, Lambert, Marc, Parienti, Jean-Jacques, Granel, Brigitte, Dumont, Anael, Sultan, Audrey, Manrique, Alain, Saadoun, David, Ly, Kim Heang, Agard, Christian, and Aouba, Achille
- Subjects
- *
GIANT cell arteritis , *AORTIC stenosis , *STENOSIS - Abstract
Large-vessel involvement (LVI) in giant cell arteritis (GCA) includes different clinical and imaging patterns that are rarely described separately at diagnosis and whose specific cardiovascular outcomes are unknown. We conducted a nationwide retrospective study and included GCA patients with LVI demonstrated on imaging at diagnosis between 2007 and 2017. We analyzed the prognosis of three different imaging patterns of LVI present at diagnosis, with some of them overlapping but with the first one present in all patients: 1) inflammation of the aorta and/or its branches; 2) dilation of the aorta; and 3) stenosis of the aortic branches. A control group of GCA patients without LVI was constituted. We included 183 patients with LVI and 105 controls without LVI. Altogether, among the 183 patients who all showed inflammation of the aorta and/or its main branches, concomitant aortic dilation and large-vessel stenosis were observed in 27 (15%) and 55 (30%) patients, respectively. During the follow-up period, new cardiovascular events occurred in 49% and 11% of LVI patients and controls, respectively (p < 0.0001). Inflammation of the aorta and/or its branches (HR: 3.42 [2.09–5.83], p < 0.0001) and large-artery stenosis (HR: 2.75 [1.80–4.15], p < 0.0001) were independent predictive factors of new cardiovascular events. Conversely, the use of an immunosuppressant besides corticosteroids was a protective factor against new cardiovascular events (HR: 0.44 [0.29–0.66], p < 0.0001) and the development of aortic dilation (HR: 0.43 [0.23–0.77], p = 0.005). This study suggests different forms of cardiovascular events according to the initial imaging pattern of LVI. • Large-vessel involvements include aortitis, aorta dilation and vascular stenoses. • These patterns exhibit different outcomes and prognoses. • More cardiovascular events occur in patients with initial large-vessel involvement. • Large-vessel stenosis was associated with the poorest outcomes. • Immunosuppressants might have a protective impact on new cardiovascular events. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
25. Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX.
- Author
-
Hadjadj J, Nguyen Y, Mouloudj D, Bourguiba R, Heiblig M, Aloui H, McAvoy C, Lacombe V, Ardois S, Campochiaro C, Maria A, Coustal C, Comont T, Lazaro E, Lifermann F, Le Guenno G, Lobbes H, Grobost V, Outh R, Campagne J, Dor-Etienne A, Garnier A, Jamilloux Y, Dossier A, Samson M, Audia S, Nicolas B, Mathian A, de Maleprade B, De Sainte-Marie B, Faucher B, Bouaziz JD, Broner J, Dumain C, Antoine C, Carpentier B, Castel B, Lartigau-Roussin C, Crickx E, Volle G, Fayard D, Decker P, Moulinet T, Dumont A, Nguyen A, Aouba A, Martellosio JP, Levavasseur M, Puigrenier S, Antoine P, Giraud JT, Hermine O, Lacout C, Martis N, Karam JD, Chasset F, Arnaud L, Marianetti P, Deligny C, Chazal T, Woaye-Hune P, Roux-Sauvat M, Meyer A, Sujobert P, Hirsch P, Abisror N, Fenaux P, Kosmider O, Jachiet V, Fain O, Terrier B, Mekinian A, and Georgin-Lavialle S
- Subjects
- Humans, Retrospective Studies, Male, Female, Aged, Treatment Outcome, Molecular Targeted Therapy methods, Tumor Necrosis Factor-alpha antagonists & inhibitors, Remission Induction, C-Reactive Protein analysis, Interleukin-1 antagonists & inhibitors, Interleukin-6 antagonists & inhibitors, Genetic Diseases, X-Linked drug therapy, Genetic Diseases, X-Linked genetics, Mutation, Glucocorticoids therapeutic use, Janus Kinase Inhibitors therapeutic use, Ubiquitin-Activating Enzymes genetics, Ubiquitin-Activating Enzymes antagonists & inhibitors, Hereditary Autoinflammatory Diseases drug therapy, Hereditary Autoinflammatory Diseases genetics
- Abstract
Objectives: Vacuoles, E1 enzyme, X-linked, autoinflammatory and somatic (VEXAS) syndrome is an adult-onset autoinflammatory disease associated with somatic ubiquitin-like modifier-activating enzyme 1 (UBA1) mutations. We aimed to evaluate the efficacy and safety of targeted therapies., Methods: Multicentre retrospective study including patients with genetically proven VEXAS syndrome who had received at least one targeted therapy. Complete response (CR) was defined by a clinical remission, C-reactive protein (CRP) ≤10 mg/L and a ≤10 mg/day of prednisone-equivalent therapy, and partial response (PR) was defined by a clinical remission and a 50% reduction in CRP levels and glucocorticoid dose., Results: 110 patients (median age 71 (68-79) years) who received 194 targeted therapies were included: 78 (40%) received Janus kinase (JAK) inhibitors (JAKi), 51 (26%) interleukin (IL)-6 inhibitors, 33 (17%) IL-1 inhibitors, 20 (10%) tumour necrosis factor (TNFα) blockers and 12 (6%) other targeted therapies. At 3 months, the overall response (CR and PR) rate was 24% with JAKi, 32% with IL-6 inhibitors, 9% with anti-IL-1 and 0% with TNFα blockers or other targeted therapies. At 6 months, the overall response rate was 30% with JAKi and 26% with IL-6 inhibitors. Survival without treatment discontinuation was significantly longer with JAKi than with the other targeted therapies. Among patients who discontinued treatment, causes were primary failure, secondary failure, serious adverse event or death in 43%, 14%, 19% and 19%, respectively, with JAKi and 46%, 11%, 31% and 9%, respectively, with IL-6 inhibitors., Conclusions: This study shows the benefit of JAKi and IL-6 inhibitors, whereas other therapies have lower efficacy. These results need to be confirmed in prospective trials., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ on behalf of EULAR.)
- Published
- 2024
- Full Text
- View/download PDF
26. Evolution and outcomes of aortic dilations in giant cell arteritis.
- Author
-
Gallou S, Agard C, Dumont A, Deshayes S, Boutemy J, Maigné G, Martin Silva N, Nguyen A, Philip R, Espitia O, Aouba A, and de Boysson H
- Abstract
Objectives: To identify factors associated with the progression of giant cell arteritis (GCA)-related or associated aortic dilations., Methods: In this retrospective study, 47 GCA patients with aortic dilation were longitudinally analyzed. Each patient underwent ≥2 imaging scans of the aorta during the follow-up. Three progression statuses of aortic dilations were distinguished: fast-progressive (FP) defined by a progression of the aortic diameter ≥5 mm/year or ≥1 cm/2 years, slow progressive (SP) by a progression of the aortic diameter >1 mm during the follow-up, and not progressive (NP) when aortic diameter remained stable., Results: Among the 47 patients with aortic dilation, the thoracic section was involved in 87 % of patients. Within a total follow-up of 89 [6-272] months, we identified 13 (28 %) patients with FP dilations, and 16 (34 %) and 18 (38 %) patients with SP and NP dilations, respectively. No differences regarding baseline characteristics, cardiovascular risk factors or treatments were observed among the 3 groups. However, FP patients more frequently showed atheromatous disease (p = 0.04), with a more frequent use of statins (p = 0.04) and antiplatelet agents (p = 0.02). Among the 27 (57 %) patients with aortitis, aortic dilation developed on an inflammatory segment in 23 (85 %). Among the FP patients who underwent aortic surgery with available histology (n = 3), all presented active vasculitis., Conclusion: This study suggests that aortic inflammation, as well as atheromatous disease, might participate in the fast progression of aortic dilation in GCA., Competing Interests: Declaration of competing interest None., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
27. Frequency and characteristics of severe relapse in giant cell arteritis.
- Author
-
Lozachmeur N, Dumont A, Deshayes S, Boutemy J, Maigné G, Silva NM, Nguyen A, Gallou S, Philip R, Aouba A, and de Boysson H
- Abstract
Objectives: To assess the frequency and characteristics of severe relapse in patients with giant cell arteritis (GCA) in a real-life setting., Methods: In a monocentric database of 530 patients, we retrospectively analysed patients who experienced at least one relapse and distinguished severe from nonsevere relapses. Severe relapse was defined by the occurrence of an ischaemic event (ophthalmologic, neurologic, digestive, limb ischaemia), the occurrence of an aortic complication (i.e. new or worsening of aortic dilation, aortic dissection), or new or worsening of vascular stenosis., Results: From the cohort of 530 patients, 242 (45.7%) patients experienced relapse at least once, including 13 (2.5% of the cohort) who experienced severe relapse. Among the 464 recorded relapses, 14 (3% of all relapses) were severe. Severe relapse corresponded to the following vascular events: a peripheral limb ischaemia in 6 patients, a visual event in 3 patients (including 2 acute anterior ischaemic anterior neuropathies), an aortic complication in 3 patients, a mesenteric ischaemia in one patient and an ischaemic stroke in one patient.When compared with the 229 patients who experienced nonsevere relapses, severe relapse patients were younger at diagnosis (p= 0.02), more frequently showed limb claudication at baseline (p< 0.0001) and fewer GCA-related cranial signs (p< 0.0001). At diagnosis, more large-vessel vasculitis on imaging (82% vs 36%, p= 0.002) were observed in patients with severe relapse. The death rate did not differ between patients with severe and nonsevere relapses., Conclusion: In a real-life setting, relapse affects nearly half of GCA patients, but severe relapse is rare., (© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
28. Tolerance of glucocorticoids in giant cell arteritis: a study of patient-reported adverse events.
- Author
-
de Boysson H, Barakat C, Dumont A, Boutemy J, Martin Silva N, Maigné G, Nguyen A, Lavergne A, Castan P, Gallou S, Sultan A, Deshayes S, and Aouba A
- Subjects
- Humans, Patient Reported Outcome Measures, Skin, Giant Cell Arteritis diagnosis, Giant Cell Arteritis drug therapy, Glucocorticoids adverse effects, Glucocorticoids toxicity
- Abstract
Objective: To assess patients' self-reported glucocorticoid (GC)-related adverse events (AEs) in a GCA population., Methods: A questionnaire was sent to the 100 patients most recently diagnosed with GCA in a tertiary centre. This questionnaire included open- and close-ended questions on the disease and GC effects. Eight primary AE areas were analysed: cardiovascular, metabolic, muscle, cognitive and psychologic, bone, cutaneous and hairiness, infective and visual complications. Including derivative subitems from preceding areas, a total of 18 GC-related AEs were analysed separately and according to GC duration., Results: Ninety patients were analysed and 89 (99%) reported at least one GC-related AE [median 6 (range 1-11)]. Cognitive and psychological changes, primarily insomnia (72%), affected 90% of patients. Cutaneous changes and muscle loss affected 70% of patients, with frequent impairment of physical autonomy (P = 0.007) associated with this event. Metabolic issues, especially weight gain (40%) and diabetes mellitus (20%), affected 49% of patients. Conversely, vision troubles and bone fractures were mentioned by 42% and 9% of patients, respectively, and more frequently in patients who received GCs for >18 months (P = 0.01 and P = 0.007, respectively). Cardiovascular changes and infections affected 30% and 26% of patients, respectively., Conclusion: This real-life study of GC tolerance assessed using a self-evaluation provides pragmatic and updated data reminding us that GC tolerance remains more noteworthy than ever. This study suggests carefully monitoring GC-related AEs during follow-up and encourages GC-sparing strategies in some patients., (© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
29. Impact of Giant Cell Arteritis and Its Treatment on the Patient's Quality of Life: A Single-Center Self-Assessment Study.
- Author
-
de Boysson H, Barakat C, Dumont A, Boutemy J, Martin Silva N, Maigné G, Nguyen A, Lavergne A, Castan P, Gallou S, Sultan A, Deshayes S, and Aouba A
- Abstract
Little is known about the impact of giant cell arteritis (GCA) and its treatment on patient-reported physical, mental, and psychic quality of life (QoL). In this monocentric study, a questionnaire was sent to the 100 last patients diagnosed with GCA and followed-up in a single tertiary center. Their physical, mental and psychic status were self-assessed via close-ended questions, the 12-item short form survey (SF-12) and the 15-item geriatric depression scale (GDS). We aimed to identify parameters that were significantly associated with moderate-to-severe disability in both physical and mental domains. Ninety patients were analyzable. Moderate to severe physical disability was found in 41 (46%) patients. In multivariate analysis, walking difficulties (OR, 95% CI 8.42 [2.98-26.82], p <0.0001), muscle mass and strength reduction (OR, 95% CI 4.38 [1.37-16.31], p = 0.01) and age >80 (OR, 95% CI 4.21 [1.44-13.61], p = 0.008) were independent findings associated with moderate to severe physical disability. Moderate to severe mental disability was found in 30 (33%) patients. In multivariate analysis, depressive mood (OR, 95% CI 11.05 [3.78-37.11], p < 0.0001), felt adverse events attributable to glucocorticoids (OR, 95% CI 10.54 [1.65-213.1], p = 0.01) and use of immune-suppressants (OR, 95% CI 3.50 [1.14-11.87], p = 0.03) were independent findings associated with moderate to severe mental disability. There was a statistically significant negative correlation between GDS and the physical and/or mental disability scores (GDS and PCS-12: r = -0.33, p = 0.0013; GDS and MCS-12: r = -0.36, p = 0.0005). In conclusion, this study identified via a self-assessment of patients with GCA some medical and modifiable findings that significantly affect their physical and mental quality of life. A better knowledge of these factors may help improve the care of GCA patients., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 de Boysson, Barakat, Dumont, Boutemy, Martin Silva, Maigné, Nguyen, Lavergne, Castan, Gallou, Sultan, Deshayes and Aouba.)
- Published
- 2021
- Full Text
- View/download PDF
30. Vascular Presentation and Outcomes of Patients With Giant Cell Arteritis and Isolated Symptomatic Limb Involvement.
- Author
-
de Boysson H, Espitia O, Liozon E, Daumas A, Vautier M, Dumont A, Granel B, Saadoun D, Planchard G, Ly KH, and Aouba A
- Subjects
- Glucocorticoids, Humans, Prognosis, Retrospective Studies, Giant Cell Arteritis complications, Giant Cell Arteritis diagnosis, Giant Cell Arteritis drug therapy, Stroke
- Abstract
Objective: The aims of this study were to describe and assess the vascular outcomes of patients with giant cell arteritis (GCA) presenting with only symptomatic isolated limb involvement (LI-GCA)., Methods: We recruited patients from 5 tertiary centers who were diagnosed with GCA based on histology or vasculitis demonstration on imaging and who presented with isolated symptomatic limb involvement at diagnosis. For each included patient, we randomly selected 3 control patients who satisfied the 5 criteria from the American College of Rheumatology at diagnosis., Results: We included 27 LI-GCA patients and 81 control patients. Compared with the controls, the patients with LI-GCA were younger (p = 0.005), exhibited a more delayed diagnosis (p = 0.006), and had lower C-reactive protein levels (p = 0.001), but they did not show more cardiovascular risk factors. Glucocorticoid use (starting and tapering doses) and relapse rates did not differ in the 2 groups, but the patients with LI-GCA received longer treatment (p = 0.02). Cardiovascular complications occurred in 67% of the patients with LI-GCA versus 21% of the control patients (p < 0.0001), especially ischemic events (p < 0.0001) including stroke (p = 0.03) and myocardial infarction (p = 0.01). Vascular surgery was required in 44% of the patients with LI-GCA versus 2% of the controls (p < 0.0001). Excluding vascular surgery, the cumulative incidence of cardiovascular complications was higher in the patients with LI-GCA (log-rank test: p < 0.0001) than in the controls (hazard ratio, 5.73; 95% confidence interval, 2.94-11.28; p < 0.0001)., Conclusions: Compared with the typical cranial form of GCA, LI-GCA has a worse cardiovascular-related prognosis. Further studies are required to determine the best management of these patients.
- Published
- 2020
- Full Text
- View/download PDF
31. The different clinical patterns of giant cell arteritis.
- Author
-
de Boysson H, Liozon E, Ly KH, Dumont A, Delmas C, and Aouba A
- Subjects
- Aged, Aged, 80 and over, Biopsy, Female, Humans, Male, Middle Aged, Phenotype, Giant Cell Arteritis diagnosis, Giant Cell Arteritis pathology, Polymyalgia Rheumatica
- Abstract
Objectives: To estimate the frequency of different clinical patterns in giant-cell arteritis (GCA) at onset., Methods: All GCA patients consecutively followed-up in two referral centers for GCA with a biopsy-proven diagnosis and/or large-vessel vasculitis (LVV) demonstrated on imaging were analysed., Results: We analysed the initial clinical presentation of 693 patients with a median age of 75 [48-94] years and including 486 (70%) women. We identified four different clinical patterns: isolated cranial GCA (in 80%), symptomatic LVV with or without associated cranial signs (9%), isolated fever or inflammatory response (9%), and isolated polymyalgia rheumatica with vasculitis (2%). A silent LVV was found in 110 (45%) out of the 247 patients without large-vessel symptoms who underwent imaging at GCA diagnosis. Symptomatic LVV patients were more frequently GC-dependent compared to other patterns (p=0.03) and showed the longest treatment duration (median: 37 [15-212] months versus <30 months for other clinical phenotypes; p=0.001)., Conclusions: This study suggests that 80% of GCA patients display a typical presentation, whereas the other 20% showed rarer presentations. Patients with symptomatic LVV required longer treatment duration.
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.